Certain cancers express high level of ED-B fibronectin (i.e. lung cancer, melanoma, colon cancer) whereas others seem to increase the ED-B isoform while they acquire a more aggressive phenotype (i.e. lymphoma, prostate cancer, thymoma/thymic carcinoma and thyroid cancer). This evidence concerns the gene FN1 and thyroid gland carcinoma.